Reflections on treatment strategies for palliative chemotherapy of pancreatic cancer

Anticancer Research

Volumn 27, Issue 4 A, 2007, Pages 1789-1794

  Klapdor, Rainer ^a   Bahlo, M ^a   Babinsky, A ^a   Brenzinger, M L ^a  

^a ZeTDT GmbH   (Germany)

Author keywords

Chemotherapy; Pancreatic cancer; Treatment strategies

Indexed keywords

CA 19-9 ANTIGEN; CAPECITABINE; CARCINOEMBRYONIC ANTIGEN; CETUXIMAB; DOCETAXEL; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; MITOMYCIN C; OXALIPLATIN; PEMETREXED;

ADULT; AGED; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; CONTROLLED STUDY; FEMALE; HOSPITAL ADMISSION; HUMAN; MAGNETIC RESONANCE ANGIOGRAPHY; MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS CANCER; PREDICTION; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CA-19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; FEMALE; HUMANS; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; MIDDLE AGED; PALLIATIVE CARE; PANCREATIC NEOPLASMS; SURVIVAL ANALYSIS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 34250783904     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (26)

1. Burris III HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD and Von Hoff DD: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clinical Oncol 15: 2403-2413, 1997.
2. Meyer F, Eichelmann K, Lippert H and Ridwelski K: Phase-II trial using gemcitabine as monochemotherapy in patients with metastasized pancreatic carcinoma. Acta Chirurgica Austriaca 35: 337-341, 2003.
3. Cartwright TH, Cohn A, Varkey JA, Chen Y-M, Szatrowski TP, Cox JV and Schulz JJ: Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer. J Clinical Oncol 20: 160-164, 2002.
4. Rocha Lima CM, Green MR, Rotche R, Miller WH Jr, Jeffrey GM, Cisar LA, Morganti A, Orlando N, Gruia G and Miller LL: Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor. J Clinical Oncol 22: 3776-3783, 2004.
5. Louvet C, Labianca R, Hammel P, Lledo G, Zampino MG, Andre T, Zaniboni A, Ducreux M, Aitini E, Taieb J, Faroux R, Lepere C and de Gramont A: Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clinical Oncol 23: 3509-3516, 2005.
6. Oettle H, Richards D, Ramanathan RK, Laethem van JL, Peeters M, Fuchs M, Zimmermann A, John W, Von Hoff D, Arning M and Kindler HL: A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. Ann Oncol 16: 1639-1645, 2005.
7. Kindler HL, Friberg G, Singh DA, Locker G, Nattam S, Kozloff M, Taber DA, Karrison T, Dachman A, Stadler WM and Vokes EE: Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clinical Oncol 23: 8033-8040, 2005.
8. Blaskowsky LS, Kulke KH, Ryan DP, Clark JW, Meyerhardt J, Zhu AX, Lawrence C and Fuchs CS: A phase II study of erlotinib in combination with capecitabine in previously treated patients with metastatic pancreatic cancer. Proc Am Soc Clin Oncol Annual Meeting 2005. Abstract No: 4099.
9. Bazin I, Garin A, Bulat J, Narimanow M, Nosov D, Titov D, Popov A, Nasyrova R and Tjulandin S: Gemzar (GEM) + mitomycin C (MMC) in patients with advanced pancreatic cancer (APC). European Cancer 35(Suppl. 4): Abstract 556: 151, 1999.
10. Stathopoulos GP, Rigatos SK, Domopoulos MA, Giannakakis T, Foutzilas G, Kouroussis C, Janninis D, Aravantinos G, Androulakis N, Agelaki S, Stathopoulos JG and Georgoulias V: Treatment of pancreatic cancer with a combination of irinotecan (CPT-11) and gemcitabine: a multicenter phase II study by the Greek Cooperative Group for Pancreatic Cancer. Ann Oncol 14: 388-394, 2003.
11. Heinemann V, Hoehler T, Seipelt A, Wein A, Golf A, Mahlberg R, Schmid B, Boeck S, Neugebauer S and Hochhaus A: Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (GemOx): a randomized phase II trial in advanced pancreatic cancer. Proc Am Soc Clin Oncol Abstract No 4030, 2005.
12. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht J, Gallinger S, Au H, Ding K, Christy-Bittel J and Parulekar W: Erlotinib plus gemcitabine compared to gemcitabine alone in patients advanced pancreatic cancer. A phase III trial of the National Cancer Institute Canada, Clinical Trial Group (NCIC-CTG). Proc Am Soc Clin Oncol: Abstract No 1, 1005.
13. Reni M, Cordio S, Milandri C, Passoni P, Bonetto E, Oliani C, Luppi G, Nicoletti R, Galli L, Bordonaro R, Passardi A, Zerbi A, Balzano G, Aldrighetti L, Staudacher C, Villa E and di Carlo V: Gemcitabine versus cisplatin, epirubicin, fluorouracil and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial. Lancet 6: 369-376, 2005.
14. Klapdor R, Müller Chr, Seutter R, Bahlo M, Peters W and Fenner C: Improvement of survival by efficacy-orientated sequential polychemotherapy of exocrine pancreatic cancer. Anticancer Res 20: 2501-2508, 2000.
15. Klapdor R, Bahlo M, Babinski A, Broemel T, Müller C and Seutter R: Sequential polychemotherapy in exocrine pancreatic cancer. Anticancer Res 23: 841-844, 2003.
16. Klapdor R, Bahlo M and Babinski A: Further evidence for prolongation of survival of pancreatic cancer patients by efficacy-orientated sequential polychemotherapy (EOSPC) based on serial tumor marker determinations (CA19-9/CEA). Anticancer Res 25: 1687-1692, 2005.
17. Klapdor R, Seutter E, Lang-Pölkow EM, Reichle H and Hinrichs A: Locoregional/systemic chemotherapy of locally advanced/metastasized pancreatic cancer with a combination for mitomycin-D and gemcitabine and simultaneous follow-up by imaging methods and tumor markers. Anticancer Res 19: 2459-2469, 1999.
18. Klapdor R, Quittmeyer M, Reusch M and Fenner C: Improvement of efficacy of gemcitabine on xenografts of human pancreatic carcinomas in nude mice by combination with mitomycin-C. European J Cancer 35(Suppl. 4): Abstract 576, 155, 1999.
19. Ardalan B and Tian E: A phase II study of weekly 24-hour infusion with high dose fluorouracil with leucovorin in colorectal carcinoma. J Clin Oncol 9: 625-630, 1991.
20. Klapdor R and Fenner C: Irinotecan (Campto R): efficacy as third/forth line therapy in advanced pancreatic cancer. Anticancer Res 20: 5209-5212, 2000.
21. Klapdor R, Martini-Svendsen J, Seutter R and Fenner C: Combination therapy with oxaliplatin+gemcitabine in advanced pancreatic cancer. European J Cancer 35(Suppl. 4): Abstract 536, 146, 1999.
22. Klapdor R (für die Arbeitsgruppe): Arbeitsgruppe Qualitätskontrolle und Standardisierung von Tumormarkertests im Rahmen der Hamburger Symposien über Tumormarker. Tumordiagnostik Ther 13:XIX-XXII, 1992. EGTM-Consensus Recommendations. Anticancer Res 19: 2785-2820, 1999.
23. EGTM Consensus Recommendations. Anticancer Res 19: 2785-2820, 1999.
24. Oettle H, Pelzer U, Stieler J, Hilbig A, Roll L, Schwaner I, Adler M, Detken S, Dörken B and Riess H: Oxaliplatin/folinic acid (FA)/5-fluorouracil (FU) [24h] (OFF) plus best supportive care versus best supportive care alone (BSC) in second-line therapy of gemcitabine- refractory advanced pancreatic cancer (CONCO 003). Proc Am Soc Clin Oncol, Abstract No: 4031, 2005.
25. Cantore M, Rabbi C, Fiorentini G, Oliani C, Zamagni D, Iacono C, Mambrini A, del Freo A and Manni A: combined Irinotecan and Oxaliplatin in Patients with Advanced Pre-Treated Pancreatic Cancer. Oncol 67: 93-97, 2004.
26. Tournigand Chr, André Th, Achille E, Lledo G, Flesh M, Mery- Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, Landi B, Colin P, Louvet C and de Gramont A: FOLFIRI followed by FOLFOX6 or Reserve Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study. J Clin Oncol 22: 229-237, 2004.